News | Breast Biopsy Systems | July 07, 2021

GE Healthcare’s Industry-First Contrast-Guided Biopsy Solution, Serena Bright, Installed in Five Major Hospitals in the United States

Serena Bright sets new standards for breast cancer detection and biopsy technology

Serena Bright sets new standards for breast cancer detection and biopsy technology

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around the United States. Serena Bright is the industry’s first contrast-guided biopsy solution, helping empower clinicians and patients in their fight against breast cancer. The technology, which received U.S. Food and Drug Administration 510(k) clearance in May 2020, allows patients to have their breast biopsy exams with contrast guidance using the same mammography equipment, in the same room, and with the same staff as the screening or diagnostic mammogram.

Among others, Serena Bright has been installed at Thomas Jefferson University Hospital (Philadelphia, Pa.), Boca Raton Regional Hospital (Boca Raton, Fla.), HCA Blake Medical Center in (Bradenton, Fla.) and Lake Medical Imaging & Breast Center (The Villages, Fla.). Health systems worldwide are implementing the Serena Bright technology in their efforts against breast cancer, with hundreds of patients already seeing results from installations across the globe.

Serena Bright provides reliable and accurate results that lead to a clear path of action, usually without further testing. In the past, clinicians have typically needed to use other imaging guidance, such as MRI, for biopsy procedures for lesions found with contrast-enhanced mammography and not seen on ultrasound. Following an abnormal mammogram, it can take several weeks to get an MRI biopsy.[1] Now as the backlog of cancer screenings caused by COVID-19 persists, delays in diagnosis are leading to some presentations at more advanced stages and poorer clinical outcomes, with one study pointing to a potential increase of 33,890 excessive cancer deaths in the U.S. alone.[2]

Serena Bright may help decrease these delays, allowing follow-up biopsy procedures to be done in a matter of days, rather than waiting several weeks for an MRI biopsy. When compared to MRI-biopsy guided therapy, the potential benefits of Contrast-Enhanced biopsy include shortened procedure time and improved overall patient experience.[3],[4]

“Especially in today’s world, as we start to regain a sense of normalcy post-pandemic, accurately identifying and confirming the extent of disease for patients is essential to getting them on the right path to a cure,” Jason Shames, M.D., Associate Director of Research, Division of Breast Imaging, Co-Director, Breast Imaging Fellowship at Thomas Jefferson University Hospital, said. “With Serena and Serena Bright, we are now able to provide our patients and treatment teams with more confident locoregional staging results in a more accelerated, cost effective way.”

Critical to this technology’s application is GE Healthcare’s SenoBright HD Contrast-Enhanced Spectral Mammography (CESM), a diagnostic breast exam with iodine-based contrast that provides high sensitivity for more accurate breast cancer diagnosis.[5] By highlighting areas of unusual blood flow to localize lesions that need to be biopsied, CESM biopsy – Serena Bright – provides excellent image quality to help improve clinical confidence.

“Now more than ever, we need to give patients answers as fast as possible while also ensuring their comfort. We are proud to bring Serena Bright to our customers during this time when clarity and results are needed more rapidly,” said Agnes Berzsenyi, President and CEO of Women’s Health and X-Ray at GE Healthcare. “We’re optimistic about the potential for this technology to significantly improve breast cancer outcomes for women.”

For more information:  www.gehealthcare.com/products/mammography/serena-bright

 

 

[1] Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E. Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile. Journal of the National Comprehensive Cancer Network : JNCCN. 2018;16(12):1451-1457.

[2] Lai A, Pasea L, Banerjee  A,  et al . Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency.  medRxiv. Preprint posted online June 1, 2020. doi:10.13140/RG.2.2.34254.82242

[3] Data on file 2020 GE Healthcare; From first to last image.

[4] Accessed on 10/16/2020:  https://www.cedars-sinai.edu/Patients/Programs-and-Services/Imaging-Center/For-Patients/Exams-by-Procedure/MRI/MR-Guided-Breast-Biopsy/MR-Guided-Breast-Needle-Core-Biopsy-Procedure-Information.aspx

[5] Daniauxet al. Arch Gynecol Obstet , 2015

Related Content

The global medical imaging and informatics market is experiencing dynamic changes with the emergence of advanced technologies, evolving clinical and administrative needs, and the introduction of new policies and regulations, which is forcing industry participants to innovate to maintain their competitive edge

Getty Images

News | Coronavirus (COVID-19) | July 26, 2021
July 26, 2021 — The global medical imaging and informatics market is experiencing dynamic changes with the emergence
Radiation oncologists urged Congress to reverse proposed CMS cuts and create more equity in access to cancer treatments

Getty Images

News | Radiation Oncology | July 26, 2021
July 26, 2021 — A record number of radiation oncologists met with Congressional leaders and staff last week as part o
Videos | Artificial Intelligence | July 22, 2021
This is an overview of trends and technologies in radiology...
64-Year-Old Man With Clear Cell Likelihood Score (ccLS) 5 Renal Masses

64-Year-Old Man With Clear Cell Likelihood Score (ccLS) 5 Renal Masses. Coronal T2-weighted single shot fast spin echo and coronal T1-weighted fat-saturated spoiled gradient echo acquired during corticomedullary phase—ccLS5 lesion outlined red for clarity.

News | Magnetic Resonance Imaging (MRI) | July 22, 2021
SurveyVitals, a leading patient experience analytics provider, announced it has joined forces with the Radiology Business Management Association (RBMA) to launch Postmarks, a real-time patient and partner feedback software solution
News | Patient Engagement | July 22, 2021
July 22, 2021 — SurveyVitals, a leading patient experie